Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
20 Oct 2007 Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks
19 Oct 2007 Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I
19 Oct 2007 Paion sees continued development rationale for Desmoteplase based on findings from phase III analysis
19 Oct 2007 Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
19 Oct 2007 Cleveland BioLabs Completes Manufacturing Process for Protectan CBLB502
19 Oct 2007 Nektar Therapeutics Issues Statement on Exubera
18 Oct 2007 SemBioSys confirms commercially viable levels of Native APO AI in safflower
18 Oct 2007 Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus(R)
18 Oct 2007 Omiganan Phase II Rosacea Study Demonstrates Promising Results
16 Oct 2007 Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
16 Oct 2007 Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
15 Oct 2007 NRP drug effective in animal models of motor neuron disease and peripheral neuropathy
13 Oct 2007 OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
13 Oct 2007 Long-Term Study Shows COPAXONE® Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
13 Oct 2007 Cyplasin-SC(TM) shows proof of efficacy in tumor bearing animals
12 Oct 2007 Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
12 Oct 2007 CuraGen Announces Top-Line Phase II Results on Velafermin
12 Oct 2007 Two-year Phase IIIb data show that the new formulation of Rebif® offers a near three-fold improvement in injection tolerability and reduced immunogenicity
12 Oct 2007 Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
12 Oct 2007 Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
12 Oct 2007 NascaCell Technologies AG and Boehringer Ingelheim sign collaboration agreement on therapeutic Microbodies(TM)
11 Oct 2007 Advitech Announces Positive Preclinical Results for Wound-Healing Application
10 Oct 2007 Biological Validation of Lead Compunds in Rheumatoid Arthritis Programme
09 Oct 2007 Jerini Initiates FDA Submission Process of New Drug Application for Icatibant in the Treatment of HAE
09 Oct 2007 Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels
06 Oct 2007 Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
06 Oct 2007 Genzyme Receives Approval to Market Elaprase(R) in Japan
05 Oct 2007 ThromboGenics and Rhein Minapharm Announce Agreement
04 Oct 2007 Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
04 Oct 2007 Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R)
04 Oct 2007 MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
03 Oct 2007 Protox completes BPH trial recruitment and announces positive interim data
03 Oct 2007 Chemokine Therapeutics Completes Patient Recruitment of CTCE-9908 Phase I/II Clinical Trial
03 Oct 2007 CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial
02 Oct 2007 FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
02 Oct 2007 BioLineRx In-Licenses Novel Peptide BL-4050 for the Treatment of Cancer
02 Oct 2007 Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
28 Sep 2007 Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
28 Sep 2007 Nuvelo Announces Publication of NU206 Study Results in Proceedings of the National Academy of Sciences of the United States of America
28 Sep 2007 Palatin Technologies, Inc. Reports positive data from an at-home study of pre- and postmenopausal women with female sexual arousal disorder treated with bremelanotide
27 Sep 2007 Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX(TM)
27 Sep 2007 Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing
27 Sep 2007 Affibody to Start Clinical Development of a New Approach for the Diagnosis of Cancer
27 Sep 2007 Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
27 Sep 2007 Cytheris Expands Interleukin-7 Clinical Development Program With International Phase I/IIa Trial In HIV
27 Sep 2007 New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
27 Sep 2007 OctoPlus in-licenses diabetes product candidate
25 Sep 2007 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
25 Sep 2007 European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
25 Sep 2007 Pacgen Announces Advances in PAC-113 Program
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 501 - 550 of 1426

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics